Literature DB >> 12563611

Imatinib alone and in combination for chronic myeloid leukemia.

Brian J Druker1.   

Abstract

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy of a drug that specifically acts on the causative lesion in a malignant disorder is a proof of principle for the concept of molecular targeted therapy. This article will review the development of imatinib as a new therapy for CML. Data regarding the use of higher than the standard dose of 400 mg of imatinib and combinations of imatinib with other antileukemic agents will be discussed in the context of emerging data regarding resistance mechanisms. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12563611     DOI： 10.1053/shem.2003.50000

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  15 in total

1.  Two lessons from the interface of genetics and medicine.

Authors:  Anthony C Allison
Journal:  Genetics       Date:  2004-04       Impact factor: 4.562

2.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

Review 3.  Validation of analytic methods for biomarkers used in drug development.

Authors:  Cindy H Chau; Olivier Rixe; Howard McLeod; William D Figg
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

4.  Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

Authors:  Jing Chen; Nathan R Wall; Kerry Kocher; Nicole Duclos; Doriano Fabbro; Donna Neuberg; James D Griffin; Yang Shi; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 5.  Recent advances in the management of gastrointestinal stromal tumors.

Authors:  Margaret von Mehren
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

Review 6.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

7.  Chromosome transfer induced aneuploidy results in complex dysregulation of the cellular transcriptome in immortalized and cancer cells.

Authors:  Madhvi B Upender; Jens K Habermann; Lisa M McShane; Edward L Korn; J Carl Barrett; Michael J Difilippantonio; Thomas Ried
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

Review 8.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

Review 9.  From the genome to the proteome--biomarkers in colorectal cancer.

Authors:  Jens K Habermann; Franz G Bader; Christian Franke; Kaja Zimmermann; Timo Gemoll; Britta Fritzsche; Thomas Ried; Gert Auer; Hans-Peter Bruch; Uwe J Roblick
Journal:  Langenbecks Arch Surg       Date:  2007-10-16       Impact factor: 3.445

10.  Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.

Authors:  Nathalie Carayol; Efstratios Katsoulidis; Antonella Sassano; Jessica K Altman; Brian J Druker; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-01-26       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.